Logo

Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Share this
Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Shots:
  • Grunenthal acquired Averitas Pharma in all stocks transaction- gained the commercialization rights for Qutenza
  • The focus of the acquisition is to expand and strengthen its footprints in the markets of US
  • Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain indication in adults respectively
Ref: Grunenthal | Image: Glarus24

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions